Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase-Reference-Cited by-同舟云学术

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase

Published:2014-11 Issue:2 Volume:86 Page:237-240
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Zauderer Marjorie G.,Drilon Alex,Kadota Kyuichi,Huberman Kety,Sima Camelia S.,Bergagnini Isabella,Sumner Dyana K.,Travis William D.,Heguy Adriana,Ginsberg Michelle S.,Holodny Andrei I.,Riely Gregory J.,Kris Mark G.,Krug Lee M.,Pietanza M. Catherine

Funder

Merck & Co., Inc.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer;von Pawel;J Clin Oncol,1999

2. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer;Eckardt;J Clin Oncol,2007

3. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer;O’Brien;J Clin Oncol,2006

4. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer;Esteller;Oncogene,2004

5. DNA methylation profiles of lung tumors;Toyooka;Mol Cancer Ther,2001

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and future perspectives for the use of temozolomide in the treatment of SCLC;Cancer Treatment Reviews;2024-09

2. Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer;Frontiers in Oncology;2024-07-31

3. New therapies in small cell lung cancer: A narrative review;Pneumon;2024-03-04

4. Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting;Frontiers in Oncology;2023-12-22

5. MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapy;Neuro-Oncology Advances;2023-12-19